Incyte Corporation (BVMF:I1NC34)

Brazil flag Brazil · Delayed Price · Currency is BRL
267.57
0.00 (0.00%)
At close: Dec 4, 2025
20.66%
Market Cap 108.94B
Revenue (ttm) 25.65B
Net Income (ttm) 6.33B
Shares Out n/a
EPS (ttm) 31.46
PE Ratio 17.20
Forward PE 12.18
Dividend n/a
Ex-Dividend Date n/a
Volume 38
Average Volume 194
Open 266.22
Previous Close n/a
Day's Range 265.41 - 267.57
52-Week Range 170.00 - 287.97
Beta n/a
RSI 57.32
Earnings Date Feb 3, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1991
Employees 2,617
Stock Exchange Brazil Stock Exchange
Ticker Symbol I1NC34
Full Company Profile

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD Financial Statements

News

There is no news available yet.